Biodesix, in collaboration with Bio-Rad and Thermo Fisher Scientific, is advancing decentralized tumor-informed and tumor-naïve MRD assays designed for clinical labs, with validation underway at Memorial Sloan Kettering Cancer Center.
CMS has released preliminary 2027 CLFS rates, with data showing weighted median payment cuts for over 1,100 test codes; annual reductions are capped at 15% from 2027 to 2029 under current policy.
The molecular test can identify multiple causes of fever from a single blood sample in about an hour, helping healthcare workers diagnose infections and respond to outbreaks more quickly.
Clinisys has integrated document intelligence into its Laboratory Solution platform, enabling labs to convert unstructured documents into searchable, governed data for improved workflow efficiency and reduced manual entry.
The patent expands intellectual property coverage for the blood-based assay ahead of its planned commercial launch.
